{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:33:44Z","timestamp":1793745224934,"version":"4.6.1"},"reference-count":40,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Radiation dose escalation for locally advanced pancreatic cancer (LAPC) using stereotactic magnetic resonance (MR)-guided online adaptive radiation therapy (SMART) or computed tomography (CT)-guided moderately hypofractionated ablative radiation therapy (HART) can achieve favorable outcomes although have not previously been compared. Methods: We performed a multi-center retrospective analysis of SMART (50 Gy\/5 fractions) vs. HART (75 Gy\/25 fractions or 67.5 Gy\/15 fractions with concurrent capecitabine) for LAPC. Gray\u2019s test and Cox proportional regression analyses were performed to identify factors associated with local failure (LF) and overall survival (OS). Results: A total of 211 patients (SMART, n = 91; HART, n = 120) were evaluated, and none had surgery. Median follow-up after SMART and HART was 27.0 and 40.0 months, respectively (p &lt; 0.0002). SMART achieved higher gross tumor volume (GTV) coverage and greater hotspots. Two-year LF after SMART and HART was 6.5% and 32.9% (p &lt; 0.001), while two-year OS was 31.0% vs. 35.3% (p = 0.056), respectively. LF was associated with SMART vs. HART (HR 5.389, 95% CI: 1.298\u201321.975; p = 0.021) and induction mFOLFIRINOX vs. non-mFOLFIRINOX (HR 2.067, 95% CI 1.038\u20134.052; p = 0.047), while OS was associated with CA19-9 decrease &gt; 40% (HR 0.725, 95% CI 0.515\u20130.996; p = 0.046) and GTV V120% (HR 1.022, 95% CI 1.006\u20131.037; p = 0.015). Acute grade &gt; 3 toxicity was similar (3.3% vs. 5.8%; p = 0.390), while late grade &gt; 3 toxicity was less common after SMART (2.2% vs. 9.2%; p = 0.037). Conclusions: Ablative SMART and HART both achieve favorable oncologic outcomes for LAPC with minimal toxicity. We did not observe an OS difference, although technical advantages of SMART might improve target coverage and reduce LF.<\/jats:p>","DOI":"10.3390\/cancers17152596","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T12:15:40Z","timestamp":1754568940000},"page":"2596","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Multi-Institutional Comparison of Ablative 5-Fraction Magnetic Resonance-Guided Online Adaptive Versus 15\/25-Fraction Computed Tomography-Guided Moderately Hypofractionated Offline Adapted Radiation Therapy for Locally Advanced Pancreatic Cancer"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8328-7518","authenticated-orcid":false,"given":"Michael D.","family":"Chuong","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Miami Cancer Institute, Miami, FL 33176, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8076-9199","authenticated-orcid":false,"given":"Eileen M.","family":"O\u2019Reilly","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1027-8981","authenticated-orcid":false,"given":"Robert A.","family":"Herrera","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Miami Cancer Institute, Miami, FL 33176, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Zinovoy","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn E.","family":"Mittauer","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Miami Cancer Institute, Miami, FL 33176, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muni","family":"Rubens","sequence":"additional","affiliation":[{"name":"Office of Clinical Research, Miami Cancer Institute, Miami, FL 33176, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1962-8351","authenticated-orcid":false,"given":"Adeel","family":"Kaiser","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Miami Cancer Institute, Miami, FL 33176, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8268-2903","authenticated-orcid":false,"given":"Paul B.","family":"Romesser","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nema","family":"Bassiri-Gharb","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Miami Cancer Institute, Miami, FL 33176, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2597-7091","authenticated-orcid":false,"given":"Abraham J.","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Cuaron","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alonso N.","family":"Gutierrez","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Miami Cancer Institute, Miami, FL 33176, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8774-1845","authenticated-orcid":false,"given":"Carla","family":"Hajj","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ucar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Miami Cancer Institute, Miami, FL 33176, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"DeZarraga","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Miami Cancer Institute, Miami, FL 33176, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Aparo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Miami Cancer Institute, Miami, FL 33176, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher H.","family":"Crane","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marsha","family":"Reyngold","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"key":"ref_1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer: A review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: The LAP07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Fietkau, R., Ghadimi, M., Gr\u00fctzmann, R., Wittel, U.A., Jacobasch, L., Uhl, W., Croner, R.S., Bechstein, W.O., Neumann, U.P., and Waldschmidt, D. (2022, January 3\u20137). Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: First results of the CONKO-007 trial. Proceedings of the 2022 ASCO Annual Meeting, Chicago, IL, USA.","DOI":"10.1200\/JCO.2022.40.16_suppl.4008"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/cncr.29161","article-title":"Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma","volume":"121","author":"Herman","year":"2015","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13014-019-1309-x","article-title":"Ablative radiation therapy for locally advanced pancreatic cancer: Techniques and results","volume":"14","author":"Reyngold","year":"2019","journal-title":"Radiat. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.ijrobp.2023.05.023","article-title":"A multi-institutional phase 2 trial of ablative 5-fraction stereotactic magnetic resonance-guided on-table adaptive radiation therapy for borderline resectable and locally advanced pancreatic cancer","volume":"117","author":"Parikh","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"110064","DOI":"10.1016\/j.radonc.2023.110064","article-title":"Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: A multi-center, open-label phase 2 study","volume":"191","author":"Chuong","year":"2024","journal-title":"Radiother. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.prro.2020.09.005","article-title":"Ablative 5-fraction stereotactic magnetic resonance\u2013guided radiation therapy with on-table adaptive replanning and elective nodal irradiation for inoperable pancreas cancer","volume":"11","author":"Chuong","year":"2021","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"100506","DOI":"10.1016\/j.adro.2020.06.010","article-title":"Ablative five-fraction stereotactic body radiation therapy for inoperable pancreatic cancer using online MR-guided adaptation","volume":"6","author":"Hassanzadeh","year":"2021","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"110347","DOI":"10.1016\/j.radonc.2024.110347","article-title":"Adaptive MRI-guided stereotactic body radiation therapy for locally advanced pancreatic cancer\u2014A phase II study","volume":"197","author":"Ejlsmark","year":"2024","journal-title":"Radiother. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Bordeau, K., Michalet, M., Keskes, A., Valdenaire, S., Debuire, P., Cantaloube, M., Cabaill\u00e9, M., Portales, F., Draghici, R., and Ychou, M. (2022). Stereotactic MR-guided adaptive radiotherapy for pancreatic tumors: Updated results of the Montpellier prospective registry study. Cancers, 15.","DOI":"10.3390\/cancers15010007"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ijrobp.2025.03.039","article-title":"Development of multiparametric prognostic models for stereotactic magnetic resonance guided radiation therapy of pancreatic cancers","volume":"122","author":"Michalet","year":"2025","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Reyngold, M., O\u2019Reilly, E., Herrera, R., Kaiser, A., Zinovoy, M., Romesser, P., Wu, A., Hajj, C., Cuaron, J., and Ucar, A. (2022). Multi-institutional comparison of ablative radiation therapy in 5 versus 15\u201325 fractions for locally advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys., 114.","DOI":"10.1016\/j.ijrobp.2022.07.534"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.ijrobp.2015.12.003","article-title":"Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation","volume":"94","author":"Krishnan","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaoncol.2021.0057","article-title":"Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer","volume":"7","author":"Reyngold","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"109869","DOI":"10.1016\/j.radonc.2023.109869","article-title":"Online adaptive radiotherapy: Assessment of planning technique and its impact on longitudinal plan quality robustness in pancreatic cancer","volume":"188","author":"Mittauer","year":"2023","journal-title":"Radiother. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.semradonc.2014.02.008","article-title":"The ViewRay system: Magnetic resonance\u2013guided and controlled radiotherapy","volume":"24","author":"Mutic","year":"2014","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ijrobp.2020.11.017","article-title":"Maximizing tumor control and limiting complications with stereotactic body radiation therapy for pancreatic cancer","volume":"110","author":"Mahadevan","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.radonc.2004.12.022","article-title":"Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma","volume":"76","author":"Hoyer","year":"2005","journal-title":"Radiother. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.21037\/jgo-20-187","article-title":"A prospective trial of stereotactic body radiation therapy for unresectable pancreatic cancer testing ablative doses","volume":"11","author":"Liauw","year":"2020","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Rudra, S., Jiang, N., Rosenberg, S., Olsen, J., Parikh, P., Bassetti, M., and Lee, P. (2017). High dose adaptive MRI guided radiation therapy improves overall survival of inoperable pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys., 99.","DOI":"10.1016\/j.ijrobp.2017.06.1042"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Simoni, N., Rossi, G., Cellini, F., Vitolo, V., Orlandi, E., Valentini, V., Mazzarotto, R., Sverzellati, N., and D\u2019Abbiero, N. (2022). Ablative radiotherapy (ART) for locally advanced pancreatic cancer (LAPC): Toward a new paradigm?. Life, 12.","DOI":"10.3390\/life12040465"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.semradonc.2023.10.013","article-title":"MRI-guided adaptive radiation therapy","volume":"34","author":"Benitez","year":"2024","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.radonc.2017.11.032","article-title":"Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen","volume":"126","author":"Henke","year":"2018","journal-title":"Radiother. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.prro.2017.10.001","article-title":"Results of a prospective phase 2 clinical trial of induction gemcitabine\/capecitabine followed by stereotactic ablative radiation therapy in borderline resectable or locally advanced pancreatic adenocarcinoma","volume":"8","author":"Quan","year":"2018","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.radonc.2020.11.006","article-title":"A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome","volume":"155","author":"Teriaca","year":"2021","journal-title":"Radiother. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13014-023-02340-2","article-title":"Review of cone beam computed tomography based online adaptive radiotherapy: Current trend and future direction","volume":"18","author":"Liu","year":"2023","journal-title":"Radiat. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1126\/science.1082504","article-title":"Tumor response to radiotherapy regulated by endothelial cell apoptosis","volume":"300","author":"Paris","year":"2003","journal-title":"Science"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"57","DOI":"10.5603\/RPOR.a2022.0005","article-title":"Radiobiology of stereotactic radiotherapy","volume":"27","author":"Mangoni","year":"2022","journal-title":"Rep. Pract. Oncol. Radiother."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Qiu, B., Aili, A., Xue, L., Jiang, P., and Wang, J. (2020). Advances in radiobiology of stereotactic ablative radiotherapy. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.01165"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.prro.2019.06.016","article-title":"Radiation therapy for pancreatic cancer: Executive summary of an ASTRO clinical practice guideline","volume":"9","author":"Palta","year":"2019","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.radonc.2020.07.052","article-title":"ESTRO ACROP guidelines for target volume definition in pancreatic cancer","volume":"154","author":"Brunner","year":"2021","journal-title":"Radiother. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1016\/j.prro.2019.07.018","article-title":"Australasian gastrointestinal trials group (AGITG) and trans-tasman radiation oncology group (TROG) guidelines for pancreatic stereotactic body radiation therapy (SBRT)","volume":"10","author":"Oar","year":"2020","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.ijrobp.2010.04.058","article-title":"Pancreatic cancer tumor size on CT scan versus pathologic specimen: Implications for radiation treatment planning","volume":"80","author":"Arvold","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijrobp.2019.01.075","article-title":"Patterns of local failure after stereotactic body radiation therapy and sequential chemotherapy as initial treatment for pancreatic cancer: Implications of target volume design","volume":"104","author":"Zhu","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/COC.0000000000000518","article-title":"Pattern of marginal local failure in a phase II trial of neoadjuvant chemotherapy and stereotactic body radiation therapy for resectable and borderline resectable pancreas cancer","volume":"42","author":"Kharofa","year":"2019","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.ijrobp.2024.10.026","article-title":"NRG Oncology International Consensus Contouring Atlas on Target Volumes and Dosing Strategies for Dose-Escalated Pancreatic Cancer Radiation Therapy","volume":"121","author":"Sanford","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"101084","DOI":"10.1016\/j.adro.2022.101084","article-title":"Causes of death among patients with initially inoperable pancreas cancer after induction chemotherapy and ablative 5-fraction stereotactic magnetic resonance image guided adaptive radiation therapy","volume":"8","author":"Chuong","year":"2023","journal-title":"Adv. Radiat. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/15\/2596\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:25:36Z","timestamp":1760034336000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/15\/2596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":40,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["cancers17152596"],"URL":"https:\/\/doi.org\/10.3390\/cancers17152596","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]}}}